Second-Line Switch to Dolutegravir Noninferior in HIV

FRIDAY, June 23, 2023 -- For patients with HIV without genotype information, a second-line switch to dolutegravir is noninferior to a regimen containing a ritonavir-boosted protease inhibitor (PI), according to a study published in the June 22 issue...